TrialInternational journal of clinical oncology2017

Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy in the SENRI trial: analysis of risk factors for vomiting and nausea.

Hiroyoshi Takemoto et al.PubMed ↗Publisher ↗

No numbers read from the abstract.